If the 12 month data proves differently than the 6 month data I would not argue with you at all about this, but in writing that I would be very cautious. GSK is not going to buy out a company that cannot deliver. Instead they would continue their partnership and holding shares of FOLD and slowly exit (mind you I am not saying that is going to happen). IMO I think that it will continue its uptrend, but the 6 month data is still weighing heavily on this company. However on any pullback under 3.75 I will repurchase this stock. Overall it is a good company and has much cash on hand to work with plus a strong pipeline.